CN Patent

CN119529057A — 长效glp-1化合物

Assigned to Gan and Lee Pharmaceuticals Co Ltd · Expires 2025-02-28 · 1y expired

What this patent protects

一种新的GLP‑1衍生物，其相比于利拉鲁肽、索玛鲁肽等已上市的GLP‑1衍生物，具有相当或更好的效力、药效或功效、更长或相当的体内持续作用时间或体内半衰期、具有更好或相当的GLP‑1受体结合亲和力、具有更好或相当的DPP‑IV稳定性。

USPTO Abstract

一种新的GLP‑1衍生物，其相比于利拉鲁肽、索玛鲁肽等已上市的GLP‑1衍生物，具有相当或更好的效力、药效或功效、更长或相当的体内持续作用时间或体内半衰期、具有更好或相当的GLP‑1受体结合亲和力、具有更好或相当的DPP‑IV稳定性。

Drugs covered by this patent

Patent Metadata

Patent number
CN119529057A
Jurisdiction
CN
Classification
—
Expires
2025-02-28
Drug substance claim
No
Drug product claim
No
Assignee
Gan and Lee Pharmaceuticals Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.